MedPharm: Simon Redgrove and Jeremy Drummond
Topical and transdermal pharmaceutical development-focused MedPharm has appointed two executives: Simon Redgrove and Jeremy Drummond.
The firm said Redgrove, who has been appointed to chairman of the board, has experience in fostering companies through growth stages of development.
“We will look to use his different perspective and strong business acumen to ensure MedPharm continues to grow in line with its ambitious strategic plan,” said CEO Andy Muddle.
Redgrove said he is joining MedPharm at an exciting time, following the recent integration of services with its US facilities in North Carolina.
“I am looking forward to helping MedPharm grow on the back of the many exciting innovations it is bring to its services to support customers’ development projects,” he said.
Redgrove has previously held positions at Cavanagh Group, Close Brothers Asset Management (which bought Close Brothers in 2011) and cofounded online investment service MunnyPot.
Drummond has been appointed as MedPharm’s vice president of business development and member of the executive leadership team.
According to the firm, Drummond’s role focuses on client relations and timeline risk management.
“Drummond’s role is to help clients understand how MedPharm can mitigate risk and shorten their development timelines of their generic or proprietary products,” said the firm.
“His commercial experience and knowledge is strongly complimented by his technical background and we are looking forward to him driving MedPharm’s presence in the global pharmaceutical CRO marketplace,” said chief scientific officer Marc Brown.
Drummond holds a PhD in organic chemistry from the University of Cambridge.